Nūhou

I nā poʻe maʻi me ka cardiomyopathy liʻiliʻi liʻiliʻi (MDCM), pili nā kiʻekiʻe kiʻekiʻe o ka protein C-reactive kiʻekiʻe (hs-CRP) me nā kiʻekiʻe kiʻekiʻe o ka N-terminal brain natriuretic peptide (NT-proBNP) i nā maʻi me ka cardiomyopathy liʻiliʻi liʻiliʻi (MDCM) .), ʻoiai ʻaʻohe mea hōʻike e kākoʻo i kahi hopena wānana e pili ana i nā hopena maʻi.Ua paʻi ʻia nā hopena ma ka puke pai ESC Heart Failure.
Ua hana ʻia kahi loiloi retrospective o nā mea maʻi me ka dilated cardiomyopathy (DCM) a me ka haʻihaʻi ventricular ejection haʻahaʻa ma lalo o 50% i komo i ka Halemai Fuwai ma Beijing, Kina mai Dekemaba 2006 a ʻOkakopa 2017.Ua ʻimi nā mea noiʻi e hoʻohālikelike i nā biomarkers NT-proBNP a me hs-CRP i nā maʻi MDCM a me nā maʻi DCM.Ma kēia haʻawina, ua wehewehe ʻia ka MDCM ma ke ʻano he ventricular end-diastolic diameter index (LVEDDi) o 33 mm / m2 a i ʻole ka liʻiliʻi i nā kāne a me 34 mm / m2 i nā wahine.
He 640 ka nui o ka poʻe i komo i loko o ka loiloi, a ʻo 17% i helu ʻia he MDCM a ʻo 83% i helu ʻia he DCM ma ka papa kuhikuhi.ʻO ka holoʻokoʻa, 24.8% o nā mea komo he wahine.ʻO ka awelika o nā makahiki o nā maʻi he 49 mau makahiki.
Ke hoʻohālikelike ʻia me nā poʻe komo DCM, ʻoi aku ka liʻiliʻi o nā maʻi MDCM, ʻoi aku ka kiʻekiʻe o ke koko, ke kiʻekiʻe o ka maʻi diabetes, ka haʻahaʻa haʻahaʻa o ka tachycardia ventricular nonsustained, ʻoi aku ka kiʻekiʻe o ke kino kino, a me ka noho pōkole pōkole. E pili ana i nā biomarkers cardiac, ʻo nā maʻi me ka MDCM he haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa median NT-proBNP i hoʻohālikelike ʻia me nā maʻi me DCM (2203 pg/mL vs 1448 pg/mL, kēlā me kēia; P <.001). E pili ana i nā biomarkers, ʻo nā maʻi me MDCM he haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa haʻahaʻa median NT-proBNP i hoʻohālikelike ʻia me nā maʻi me ka cardiac DCM (2203 pg/mL vs 1448 pg/mL, kēlā me kēia; P <.001). Что кааетсиетаехациее NT-Docона MPSеетижен на Ma keʻano o nā biomarkers cardiac, ua haʻahaʻa loa nā maʻi MDCM i nā pae NT-proBNP i hoʻohālikelike ʻia me nā maʻi DCM (2203 pg / mL vs. 1448 pg / mL, kēlā me kēia; P <0.001).关于心脏生物标志物，与DCM 患者相比，MDCM 患者的NT-proBNP 水平中位数显着降低（p4）着降低（p4（分1低（3（1） pL0分1/2m2.MDCM 患者的NT-proBNP 水平中位数显着降低（分别，与2203 pg/mL 和L0.0 pg/mL 和L0.0 On anaikiki ч касаетаныха - у сновен оль И сноетаетаее NM " Ma nā huaʻōlelo o nā biomarkers cardiac, ʻoi aku ka haʻahaʻa o nā pae NT-proBNP i nā maʻi MDCM i hoʻohālikelike ʻia me nā maʻi DCM (2203 pg / mL a me 1448 pg / mL, kēlā me kēia; P <0.001).ʻO ka hoʻohālikelike, ʻoi aku ka nui o nā pae hs-CRP i nā maʻi MDCM ma mua o nā maʻi DCM (3.09 mg / L a me 2.79 mg / L, kēlā me kēia; P = 0.39).
Ma waena o nā maʻi 282 i loaʻa i ka echocardiographic follow-up i nā manawa o 6 mau mahina a i ʻole, ua hoʻomohala ʻia nā maʻi 7 me MDCM (11.1%) i ka DCM, aʻo nā maʻi 70 me DCM (32.0%) i hoʻi i MDCM, e like me ka hoʻololi ʻana i LVEDDi.
He haʻahaʻa haʻahaʻa ko ka poʻe maʻi MDCM kumu o ka make ʻana o nā kumu āpau, ka hoʻololi ʻana o ka naʻau, a me ka heluhelu ʻana no ka pau ʻole o ka naʻau i hoʻohālikelike ʻia me nā mea komo DCM (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43-0.93; P = 0.019).
ʻO nā pae hs-CRP a me NT-proBNP i pili kūʻokoʻa me ka hopena i hui pū ʻia ma ka pūʻulu haʻawina holoʻokoʻa (hs-CRP, aHR, 1.07; 95% CI, 1.00-1.15 a me NT-proBNP: aHR, 1.11, 95% CI, 1.02–1.22, p = 0.019).
Ma hope o ka hoʻohālikelike ʻana i nā helu propensity ma waena o MDCM a me DCM, ua kūlike ka hui ma waena o nā kiʻekiʻe kiʻekiʻe o NT-proBNP a me ka hopena i hui ʻia me ka mea i hōʻike ʻia ma mua o ka hoʻohālikelike ʻana i nā maʻi me DCM (RR, 1.83; 95% CI, 1.05-3.20; P = 0.034), akā,ʻaʻole i nā maʻi me MDCM (HR, 1.54, 95% CI, 0.76-3.11, P = 0.227).I ka hoʻohālikelike ʻana, ua pili nui nā pae hs-CRP me ka prognosis i nā maʻi me MDCM (RR 3.19; 95% CI 1.52-6.66; P = 0.002), akā ʻaʻole i nā maʻi me DCM (RR 1.04; 95% CI).0.61–1.79;p = 0.88).
ʻO kahi palena o ke aʻo ʻana ʻo ia ka loli ʻana o ka phenotype o nā maʻi i ka wā o ka hahai ʻana, ʻoiai he liʻiliʻi ka helu o ka poʻe i hana hou i ka echocardiography, no laila ʻaʻole i nānā ʻia nā wānana o ka hoʻololi phenotypic.Eia kekahi, ma muli o ka liʻiliʻi liʻiliʻi o nā mea maʻi MDCM i ke aʻo ʻana, ʻaʻole i hoʻoponopono piha ʻia nā mea hoʻohaunaele no ka loiloi multivariate.
"Hoʻopili ʻia ka baseline hs-CRP me nā hopena i hui ʻia i nā maʻi MDCM ma mua a ma hope o ka hoʻoponopono ʻana no nā covariates, ʻoiai ʻo NT-proBNP i pili wale me nā hopena ma DCM," i kākau ʻia e nā mea kākau."Pono ʻia nā noiʻi hou aʻe e noiʻi i nā wānana o nā loli i ka geometry ventricular a me ka hana naʻau, ʻoi aku hoʻi i nā mea maʻi me MDCM, e hāʻawi i ka stratification pilikia."
Hōʻike: ʻAʻohe o nā mea kākau noiʻi i ʻōlelo pili me ka biotech, pharmaceutical, a / a i ʻole nā ​​​​hui mea hana.
Feng J, Tian P, Liang L, a me al.Ka hopena a me ka waiwai prognostic o N-terminal pro-brain natriuretic peptide a me ka kiʻekiʻe-sensitivity C-reactive protein i nā cardiomyopathies māmā a dilated.ESC puʻuwai hāʻule.Paʻi ʻia ma ka pūnaewele 4 Malaki 2022 doi: 10.1002/ehf2.13864
Kuleana kope © 2022 Haymarket Media, Inc. Ua mālama ʻia nā kuleana a pau.ʻAʻole hiki ke paʻi ʻia, hoʻolaha ʻia, kākau hou ʻia a hoʻolaha ʻia paha ma kekahi ʻano me ka ʻole o ka ʻae mua ʻia. ʻO kou hoʻohana ʻana i kēia pūnaewele ka ʻae ʻana i ke kulekele pilikino a me nā ʻōlelo a me nā Kūlana o Haymarket Media. ʻO kou hoʻohana ʻana i kēia pūnaewele ka ʻae ʻana i ke kulekele pilikino a me nā ʻōlelo a me nā Kūlana o Haymarket Media.ʻO kou hoʻohana ʻana i kēia pūnaewele ʻo ia kou ʻae ʻana i ke kulekele pilikino a me nā ʻōlelo a me nā Kūlana Haymarket Media.ʻO kou hoʻohana ʻana i kēia pūnaewele ʻo ia kou ʻae ʻana i ke kulekele pilikino a me nā ʻōlelo a me nā Kūlana Haymarket Media.
Ua nānā ʻoe i {{metering-count}} o {{metering-total}} ʻatikala i kēia mahina.Heluhelu palena ʻole me ke komo manuahi a hoʻopaʻa inoa.
E hoʻopaʻa inoa no ka manuahi a loaʻa iā ʻoe ke komo palena ʻole i: - Nūhou Clinical - Nā noiʻi hihia - Nā hōʻike ʻaha kūkā - Nā lako piha - Nā monograph lāʻau lapaʻau - etc.